
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39261512
71535
10.1038/s41598-024-71535-8
Article
Symptom burden, coagulopathy and heart disease after acute SARS-CoV-2 infection in primary practice
Colleran Roisin 12
Fitzgerald Sean 1
Rai Himanshu 12
McGovern Laurna 1
Byrne Roger J. 3
Mansur Ahmed 3
Cradock Andrea 4
Lavery Ros 3
Bisset James 3
McKeogh Shane 5
Cantwell Gordon 6
O’Ciardha Darach 7
Wilson Hannah 1
Begossi Nicoletta 1
Blake Nial 1
Fitzgibbon Maria 8
McNulty Jonathan 4
Széplaki Gábor 1
Heffernan Emma 8
Hannan Margaret 8
O’Donnell James S. 9
http://orcid.org/0000-0001-5224-6393
Byrne Robert A. robert.byrne@materprivate.ie

12
1 Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland
2 https://ror.org/01hxy9878 grid.4912.e 0000 0004 0488 7120 School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
3 Mater Private Network, Dublin, Ireland
4 https://ror.org/05m7pjf47 grid.7886.1 0000 0001 0768 2743 School of Medicine, University College Dublin, Dublin, Ireland
5 Solas Medical Centre, Dublin, Ireland
6 Drs Cantwell and Spillane Practice, Family and General Medicine, Dublin, Ireland
7 https://ror.org/02tyrky19 grid.8217.c 0000 0004 1936 9705 Institute of Population Health, Trinity College Dublin, Dublin, Ireland
8 Department of Pathology, Mater Private Network, Dublin, Ireland
9 https://ror.org/01hxy9878 grid.4912.e 0000 0004 0488 7120 Irish Centre for Vascular Biology, RCSI University of Medicine and Health Sciences, Dublin, Ireland
11 9 2024
11 9 2024
2024
14 2122912 12 2023
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
SETANTA (Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland) study aimed to investigate symptom burden and incidence of cardiac abnormalities after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 and to correlate these results with biomarkers of immunological response and coagulation. SETANTA was a prospective, single-arm observational cross-sectional study condcuted in a primary practice setting, and prospectively registered with ClinicalTrials.gov (identifier: NCT04823182). Patients with recent COVID-19 infection (≥ 6 weeks and ≤ 12 months) were prospectively enrolled. Primary outcomes of interest were markers of cardiac injury detected by cardiac magnetic resonance imaging (CMR), which included left ventricular ejection fraction, late gadolinium enhancement and pericardial abnormalities, as well as relevant biomarkers testing immunological response and coagulopathy. 100 patients (n = 129 approached) were included, amongst which 64% were female. Mean age of the total cohort was 45.2 years. The median (interquartile range) time interval between COVID-19 infection and enrolment was 189 [125, 246] days. 83% of participants had at least one persistent symptom, while 96% had positive serology for prior SARS-CoV-2 infection. Late gadolinium enhancement, pericardial effusion, was present in 2.2% and 8.3% respectively, while left ventricular ejection fraction was below the normal reference limit in 17.4% of patients. Von Willebrand factor antigen was elevated in 32.7% of patients and Fibrinogen and D-Dimer levels were found to be elevated in 10.2% and 11.1% of patients, respectively. In a cohort of primary practice patients recently recovered from SARS-CoV-2 infection, prevalence of persistent symptoms and markers of abnormal coagulation were high, despite a lower frequency of abnormalities on CMR compared with prior reports of patients assessed in a hospital setting.

Trial Registration: Clinicaltrials.gov, NCT04823182 (prospectively registered on 30th March 2021).

Keywords

COVID-19
Inflammation
Biomarkers
Magnetic resonance imaging
Subject terms

Respiratory signs and symptoms
Biomarkers
Cardiology
Partly supported by a research grant to Roisin Colleran from Women As One2021 Escalator award - Research Colleran Roisin issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 first emerged in Wuhan, China in December 2019. With its rapid spread across every continent and its significant mortality and morbidity, there has been considerable interest in the cardiovascular complications of infection, with myocardial injury having been noted to be widely prevalent1,2. Mechanisms of myocardial injury include acute coronary syndrome, exacerbation of pre-existing cardiovascular disease, arrhythmia, and myocarditis3–5. Microvascular angiopathy, endothelial dysfunction as well as coagulopathy have been suggested as mediators of the more severe cardiovascular sequelae of the disease6. While short term complications are best described in recent times, more information has also emerged about the long-term cardiovascular complications of COVID-197,8.

Several studies assessing the effect of COVID-19 on myocardial tissue through the medium of cardiac magnetic resonance (CMR) imaging have been published. In 2020, Puntmann et al. reported results from a prospective observational cohort study that included 100 patients recently recovered from COVID-199. CMR revealed cardiac involvement in 78% of patients with ongoing myocardial inflammation in 60%, as well as a substantial number with scarring evident on native longitudinal relaxation time (T1) and late gadolinium enhancement (LGE) assessment. Similar data has been reproduced in several studies with varying designs, which have been generally small10,11 or have focused on specific populations such as recovering athletes12.

There has also been significant interest in terms of immunity and coagulopathy post COVID-19 infection. The immunological response to the disease, although investigated in detail at this point, is still not fully understood. Severe cases of COVID-19 tend to have a more vigorous IgG response against SARS-CoV-2 compared with mild cases13. A prior study found that anti-SARS-CoV-2 antibodies to the spike protein decreased over 60 days in health care personnel, with 58% of seropositive individuals becoming seronegative14. Moreover, it has been shown that patients with SARS-CoV-2 are at higher risk of arterial and venous thrombotic events with reports of venous thromboembolism prevalence of up to 69% in critically ill patients15. Elevations in Von-Willebrand factor (VWF) or D-dimer many months post recovery, even in a non-ICU cohort, potentially point towards continued coagulopathy and likely indicate ongoing endothelial dysfunction weeks or months post initial illness16.

Thus, the aims of this study were to investigate the (i) incidence of cardiac abnormalities as assessed by CMR imaging in unselected patients after acute COVID-19 infection in Ireland, and (ii) to examine the correlation with immunological response and biomarkers of coagulation.

Materials and methods

Study design and participants

SETANTA was a prospective, community-based, observational cross-sectional study. All consecutive patients with recent COVID-19 infection were identified at three primary care centres in Ireland and invited to participate in the study. Key study inclusion criteria were (i) ≥ 18 years, (ii) SARS-CoV-2 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 nasopharyngeal swab, and (iii) written informed consent. Key exclusion criteria were (i) prior history of myocarditis or ischemic heart disease, (ii) contraindication to gadolinium (eGFR < 30 ml/min) or regadenoson (including cardiac conduction disease, asthma, seizures, pregnancy or breast-feeding), (iii) inability to provide written informed consent, fill out the safety questionnaires or cooperate with the scan and breath holds, (iv) insufficient CMR image quality. This study was approved by local hospital Institutional Review Board (Ref. No. 1/378/2199) and conducted in accordance with the Declaration of Helsinki. A written informed consent was obtained from all participants prospectively during their screening visit. The study was also prospectively registered on http://www.cliniclatrials.gov platform (ClinicalTrials.gov identifier: NCT04823182).

Pre-specified outcomes of interest

The primary outcomes of interest were markers of cardiac injury detected by CMR, including, left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV), right ventricular ejection fraction (RVEF), native T1, native transverse relaxation time (T2), late gadolinium enhancement, and pericardial abnormalities. Secondary outcomes included anti-SARS-CoV-2 antibody testing and markers of coagulation and immunity.

Data collection

Eligible patients, who provided written informed consent, were invited to attend a baseline visit over two consecutive days at a hospital clinic. The first visit comprised of consent and collation of baseline demographics, medical history, current medications, and self-reported SARS-CoV-2 symptoms. Symptoms were self-defined by patients as mild, moderate, severe or none. A modified version of the SAQ7 (Seattle Angina Questionnaire 7) was used to assess anginal-type symptoms. Assessments included vital signs, electrocardiogram (ECG), 24-h ambulatory ECG recording and blood sampling by a dedicated study nurse. The patient returned to the hospital clinic after 24 h and underwent CMR imaging. Incidence of major adverse cardiac events (MACE) were followed up via telephone at 1, 6 and 12 months following the baseline visit, with changes in QOL indices reviewed at months 6 and 12.

Cardiac magnetic resonance imaging

Cardiac magnetic resonance (CMR) imaging was performed on a 1.5 T whole body scanner (Magnetom Sola, Siemens Healthcare Sector, Erlangen, Germany). Full details with regard to baseline sequences are provided in the Supplementary appendix. Perfusion imaging was carried out after the administration of 0.4 mg of regadenoson as a rapid bolus over 10 s. This was followed by 0.1 mmol/kg of the gadolinium-based contrast agent gadobutrol (Gadovist; Bayer Phama, Berlin, Germany) infused 45 to 60 s after. Late gadolinium enhancement (LGE) imaging was carried out in HLA, VLA, LVOT and short axis views with cross-cut imaging over any apparent LGE, 10 min after administration of gadolinium.

Electrocardiogram assessment

Standard published definitions were used for ambulatory ECG parameters17. For further details, please see the Supplementary appendix.

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Results

A cohort of 100 patients was included between February and September 2021, of which 96 underwent CMR imaging (Supplementary Fig. 1). The median (IQR) time interval between SARS-CoV-2 infection and enrolment was 189 (125, 246) days. Mean age was 45.2 ± 12.8 years. The majority of subjects were females (64%), with a mean BMI of 27.1 ± 5.2 kg/m2. Patients had a high prevalence of hypercholesterolemia and smoking history (20% and 41%, respectively). Baseline characteristics are shown in Table 1.Table 1 Baseline characteristics.

Participants	100	
Age, y	45.2 ± 12.8	
Female, sex	64 (64)	
Ethnicity, Caucasian	96 (96)	
Blood pressure (systolic), mmHg	133.9 ± 16.4	
Blood pressure (diastolic), mmHg	82.2 ± 10.6	
Heart rate, bpm	73.0 ± 12.0	
Height, m	1.7 ± 0.1	
Weight, kg	78.4 ± 17.8	
BMI, kg/m2	27.1 ± 5.2	
Oxygen saturation, %	97.7 ± 1.2	
Temperature, °C	36.5 ± 0.4	
Duration since index SARS-CoV-2 diagnosis (days)	189 (125, 246)	
History of hypertension	12 (12)	
History of diabetes mellitus	1 (1)	
History of Hypercholesterolemia	20 (20)	
History of Heart failure	0 (0)	
History of chronic obstructive pulmonary disease/asthma	7 (7)	
History of stroke	1 (1)	
History of deep vein thrombosis/pedal oedema	5 (5)	
 New onset deep vein thrombosis/pedal oedema	3/5 (60)	
History of renal disease	1 (1)	
History of liver disease	1 (1)	
History of smoking	41 (41)	
 Current	9/41 (22)	
 Ex-smoker	32/41 (78)	
Average alcohol intake (units/week)	8.3 ± 7.9	
Family history of premature coronary artery disease	17 (17)	
Long-term medications	
 Aspirin	3 (3)	
 Anticoagulants	3 (3)	
 Angiotensin II receptor blockers	5 (5)	
 Angiotensin-converting enzyme inhibitor	1 (1)	
 Calcium channel blocker	3 (3)	
 Lipid-lowering therapy	7 (7)	
 Colchicine	2 (2)	
 Antiarrhythmics	2 (2)	
SARS-CoV-2 infection	
 Hospitalized for index SARS-CoV-2 infection	14 (14)	
  Ventilatory support	3/14 (21)	
  Invasive	1/3 (33)	
 Hospitalization length (days)	3 (1, 6.75)	
 Non-cardiac symptoms since infection	
  Fever, % (persistent, resolved, never)	3, 50, 47	
  Sore throat, % (persistent, resolved, never)	2, 29, 69	
  Cough, % (persistent, resolved, never)	4, 49, 47	
  Myalgia, % (persistent, resolved, never)	11, 63, 26	
  Loss of sense of smell, % (persistent, resolved, never)	17, 32, 51	
  Loss of sense of taste, % (persistent, resolved, never)	15, 31, 54	
  Fatigue/Malaise, % (persistent, resolved, never)	43, 43, 14	
  Headache, % (persistent, resolved, never)	22, 44, 34	
  Rash, % (persistent, resolved, never)	1, 9, 90	
  GI disturbance, % (persistent, resolved, never)	6, 33, 61	
 Symptom severity during infection	
  Severe	18 (18)	
  Moderate	35 (35)	
  Mild	43 (43)	
  None	4 (4)	
Vaccination status	
 Vaccinated for SARS-CoV-2 at index visit (at least one dose)	60 (60)	
  Only one dose	18/60 (30)	
  Fully vaccinated	44/60 (73.3)	
 Type of vaccine	
  Pfizer	34/60 (56.7)	
  AstraZeneca	21/60 (35)	
  Moderna	3/60 (5)	
  Janssen	2/60 (3.3)	
Data expressed as number (%), mean ± SD or median (interquartile range).

Clinical status at index infection and at baseline

Nearly half of patients reported mild symptoms (43%), with 18% reporting severe symptoms during the index infection. A total of 14 patients (14%) required hospitalization, with 3 patients in this group receiving ventilatory support. Median hospital stay was 3 days (1, 6.75) (Table 1). The most common non-cardiac symptoms since infection included fatigue/malaise in 86% (persistent in 43%), myalgia in 74% (persistent in 11%), cough in 53% (persistent in 4%), fever in 53% (persistent in 3%), loss of sense of taste in 46% (persistent in 15%), loss of sense of smell in 45% (persistent in 17%) and sore throat in 31% (persistent in 2%) (Table 1).

In terms of cardio-respiratory symptoms following the SARS-CoV-2 diagnosis, a significant number of patients reported chest pain (41%), palpitations (54%), dizziness/lightheadedness (53%), and dyspnoea (62%). The majority of patient symptoms were classified as NYHA Class I (41%), with 23% reporting NYHA Class IV dyspnoea (Table 1, Fig. 1B). With regard to chest pain, 23% of patients were deemed to have severe anginal equivalent symptoms. Overall, 83% of patients had any ongoing symptom. The mean self-reported health score on EQ-5D-5L questionnaire at inclusion was 78.1 ± 16.2.Fig. 1 Cardio-respiratory symptoms following SARS-CoV-2 diagnosis. This figure highlights the percentages of patients with cardiorespiratory symptoms.

Results of biochemical and serological testing

At inclusion, 60% of patients had received at least one dose of a vaccine (Table 1). 86% of patients had a positive antibody test against the SARS-CoV-2 nucleocapsid (NCP), while 96% had a positive antibody test against the SARS-CoV-2 spike protein at inclusion. Von Willebrand factor antigen was elevated in 32.7% of patients, while Fibrinogen and D-Dimer levels were raised in 10.2% and 11.1% of patients, respectively. Inflammatory markers were elevated in a considerable proportion of patents (ferritin in 32.7%, LDH in 33.7%) (Table 2 and Supplementary Figs. 2 and 3).Table 2 Biochemical and serological parameters.

	Reference	Results	Above WNL	
Roche Elecsys Spike Protein Total Antibody Assay	
 Positive	–	86 (86)	–	
 Equivocal	–	1 (1)	–	
 Negative	–	13 (13)	–	
Roche Elecsys NCP total antibody assay	–			
 Positive	–	96 (96)	–	
 Negative	–	4 (4)	–	
White blood cells, × 109/L	4.00–11.00	6.2 ± 1.8	2 (2)	
Haemoglobin, g/dL	11.5–16.5	13.9 ± 1.5	3 (3)	
Platelets, × 109/L	150–400	231.8 ± 50.1	0 (0)	
Neutrophils, × 109/L	2–7.5	3.5 ± 1.2	1 (1)	
Lymphocytes, × 109/L	1.50–4.00	1.9 ± 0.5	0 (0)	
D-dimer, µg/mL	< 0.50	0.4 ± 0.9	11 (11.1)	
Fibrinogen, g/L	2.0–4.0	3.2 ± 0.6	10 (10.2)	
Prothrombin time, s	11.4–15.0	13.4 ± 2.5	4 (4)	
International normalized ratio	≤ 1.0	1.0 ± 0.2	11 (11)	
Activated partial thromboplastin clotting time, s	25.1–32.9	28.7 ± 2.8	5 (5)	
Creatinine, μmol/L	45–84	71.9 ± 14.2	26 (26)	
C-reactive protein, mg/L	< 5.0	2.9 ± 3.5	10 (10)	
Troponin T- HS, ng/L	Males < 22.0, females < 14.0	7.9 ± 2.1	0 (0)	
NT-proB-type, ng/L	< 125	81.1 ± 136.7	12 (12)	
Ferritin, µg/L	13–150	116.8 ± 87.3	32 (32.7)	
Lactate dehydrogenase, U/L	135–214	201.7 ± 32.1	32 (33.7)	
von Willebrand factor-antigen, IU/mL	0.5–1.5	1.3 ± 0.8	32 (32.7)	
Soluble ST2, pg/mL	6.74–20.4	30.0 ± 9.8	31 (40.3)	
Galectin-3, ng/mL	< 17.8	15.4 ± 4.3	15 (19.5)	
Data expressed as number (%) or mean ± SD. NCP, nucleocapsid; WNL, within normal limits. D-dimer was available for 99, fibrinogen, ferritin and von Willebrand factor-antigen for 98, lactate dehydrogenase for 95, and ST-2 and galectin-3 for 77 cases. The remaining parameters were available for all 100 cases.

Cardiac imaging findings

CMR parameters are summarized in Table 3. Stress perfusion imaging was normal for all included patients. Late gadolinium enhancement was present in 2 patients (Supplementary Fig. 4A). A total of 8 patients recently recovered from COVID-19 had a pericardial effusion (Supplementary Fig. 4B). Mean LVEF (short axis) was 60.8 ± 5.7%, with a LVEF below 55% in 17.4% of patients (Supplementary Fig. 4C). Although a majority of our cohort were female (64%), 62.5% (10/16 patients) with abnormal left ventricular ejection fraction (short Axis, %) were male. In the 16 cases with abnormal left ventricular ejection fraction (short Axis, %), there were 6 cases (37.5%) in NYHA I class, 4 (25%) in NYHA II class and 3 (18.8%) each in NYHA III and IV class respectively. Amongst our analysed cohort, mean native T1 (ms) was 994.4 ± 29.2 ms, post-contrast T1 was 521.4 ± 37.5 ms, mean T2 basal was 49.3 ± 2.5 ms, mean T2 mid was 50.3 ± 3.1 ms, mean T2 apical was 52.5 ± 3.8 ms, while extracellular volume was 27.5 ± 4.4%.Table 3 Cardiac magnetic resonance imaging results.

		Reference range	Abnormal	
Left ventricular ejection fraction (short axis, %)	60.8 ± 5.7	57–77*	16 (17.4)	
Left ventricular ejection fraction (axial, %)	60.8 ± 5.1	–	–	
Left ventricular end diastolic volume (ml)	155.9 ± 35.2	–	–	
Right ventricular ejection fraction (short axis, %)	59.6 ± 5.5	Female, 51–71; male, 52–72*	8 (9.5)	
Right ventricular end diastolic volume (ml)	161.1 ± 36.7	–	–	
Native T1 (ms)	994.4 ± 29.2	990.8 ± 34.3**	–	
Post-contrast T1 (ms)	521.4 ± 37.5		–	
Extracellular volume %	27.5 ± 4.4	–	–	
T2 basal (ms)	49.3 ± 2.5	47.3 ± 1.8***	–	
T2 mid (ms)	50.3 ± 3.1	47.7 ± 2.2***	–	
T2 apical (ms)	52.5 ± 3.8	49.8 ± 3.1***	–	
Left atrium size (cm2)	20.7 ± 3.8	Female, 13–27; male, 15–29*	5 (5.2)	
Right atrium size (cm2)	20.3 ± 3.9	14–30*	1 (1.0)	
Inferior vena cava size (cm)	1.7 ± 0.3	–	–	
Stress perfusion imaging (abnormal)	0 (0)	–	–	
Late gadolinium enhancement (abnormal)	2 (2.2)	–	–	
Pericardial effusion		–	–	
 Minimal	3 (3.1)	–	–	
 Small	4 (4.2)	–	–	
 Moderate	1 (1.0)	–	–	
Data expressed as number (%) or mean ± SD. Data for T2 basal and mid, left and right atrium size and pericardial effusion was available for 96, left ventricular ejection fraction (axial, %) and native T1 for 95, and Inferior vena cava size for 94, post-contrast T1 and late gadolinium enhancement for 93, left ventricular ejection fraction (short axis, %) and left/right ventricular end diastolic volume for 92, stress perfusion imaging for 89, extracellular volume for 87, and right ventricular ejection fraction (short axis, %) for 84 cases.

*Petersen et al.38. **Reference values derived from 18 age, sex and scanner matched controls. ***Reference values derived from 28 age, sex and scanner matched controls.

Results of our electrocardiography analysis are displayed as Supplementary Table 1 and Supplementary Fig. 5, and discussed in detail in our Supplementary appendix.

Clinical follow-up at 1 year

In total 99, 100 and 97 patients completed their 1, 6 and 12-month telephone follow-ups respectively. There were no significant events or overnight hospitalizations reported at 6-months follow-up time point, and one case of hospitalization for 7 nights for fever of unknown origin reported at 12 months follow-up. All 100 patients completed their SAQ7 and EQ-5D-5L questionnaires at baseline, while 75 and 72 patients, respectively, completed both their questionnaires at 6- and 12-month follow-up timepoints; responses are displayed as Fig. 2. Improvement is evident over time in terms of symptoms as well as quality of life of included subjects though the follow-up period.Fig. 2 (A) Responses for modified version of SAQ7 (Seattle Angina Questionnaire, short form) at baseline, 6 months and 12 months follow-up. Individual panels highlight responses to each question at baseline, 6-month follow up and 12 month follow up. Note that as these were otherwise healthy patients, without a diagnosis of ischemic heart disease, and not prescribed regular or as required nitroglycerin, the question with regard to nitroglycerin was omitted. (B) Responses for EQ-5D-5L (EuroQol 5-dimension 5 level) quality-of-life questionnaire at baseline, 6 months and 12 months follow-up. Individual panels highlight responses to each question at baseline, 6-month follow up and 12 month follow up. The final panel displays the mean overall “Health Score” at baseline, 6 months and 12 months.

Study highlights are visually presented as Fig. 3.Fig. 3 SETANTA study highlights.

Discussion

Summary

This study demonstrates that in an unselected patient cohort, recovering from COVID-19, cardiac abnormalities on CMR were not infrequent, although generally mild, with late gadolinium enhancement present in only 2.2% and abnormal LVEF in 17.4% of patients, despite 83% of patients reporting persistent symptoms. In terms of the aetiology of these findings, while causality cannot be inferred, they might conceivably be a consequence of COVID-associated myocarditis18. However, given the propensity for pro-coagulatory states in the setting of COVID-19, they may also be a consequence of COVID-19 related myocardial infarction, microvascular thrombosis, or endothelial inflammation related to COVID-1919,20. There is also the possibility of an association with COVID-19 induced Takotsubo cardiomyopathy, although this seems less likely21. The presence of a pericardial effusion likely signifies an association with generalized inflammation, not necessarily specific to myocarditis, but may often be seen in this setting. Markers of coagulation and inflammation remained elevated in a significant number of patients at a median of 189 days since their index diagnosis. Overall, these findings are in keeping with the fact that COVID-19 may be viewed as an endothelial disease22–24.

Strengths and limitations

This is the first prospective study in an Irish setting on patients with a COVID-19 infection who underwent evaluation for cardiac abnormalities. It has the advantage of integrating a quantification of symptom burden, biochemical and immunological markers with CMR data, allowing for the assessment the effects of COVID-19 in several domains. Furthermore, to our knowledge, it is the only study of its kind involving patients identified through primary practice, rather than in an in-patient setting. This is significant as there may be marked differences between those patients who required immediate hospitalisation for COVID-19 compared to those who did not, or ended up being admitted at a later date.

Nonetheless, our study has several limitations. Firstly, although primary care centre records were used to identify consecutive patients who have had SARS-CoV-2 infection, it was the patient’s decision to undergo enrolment (or not). While selection bias for inclusion is less than in studies enrolling patients referred to hospital for assessment, patients with persistent or troubling symptoms were more likely to be interested in taking part, and the frequency of patients with persistent symptoms thus may be overestimated. The magnitude of this overestimation is likely to be at least moderate25. Secondly, lack of baseline pre-COVID-19 imaging or laboratory tests for context constitutes a major limitation. We cannot provide information on the change of a parameter over time, or whether it was elevated prior to, or at the time of the index COVID-19 infection. Thus, in the context of this observational cohort study, causality cannot be inferred. Of note, this is, however, similar to the approach of Puntmann et al.9, whose findings we sought to replicate and given the fact that by design, our recruits were healthy volunteers from primary practice, it would not be expected that these patients would have undergone extensive cardiac testing in the past. Furthermore, our study had no direct control arm, and comparison of our patients directly against healthy controls would have been ideal. However, age, sex and MRI scanner specific data from the general population was used to generate the reference range for native T1 and T2 values, in order to mitigate the effects of this issue to some degree. Furthermore, due to the evolution of the COVID-19 virus and the interval development of several new variants, the current relevance of this data relating to infections from the time period of February–September 2021 is less clear. Thirdly, the study cohort was relatively homogenous in terms of ethnicity and age, where a majority of participants were Caucasian and relatively young.

Comparison with existing literature

Our work is similar to previously published articles in that it confirms a significant burden of “long Covid”, i.e. post-COVID-19 syndrome. These findings are similar to an Italian study that followed 143 patients recently discharged from the hospital after recovery from COVID-19. At a mean of 60.3 days after onset of the first COVID-19 symptom, 87.4% of patients reported persistence of at least 1 symptom, particularly fatigue and dyspnoea26. A longitudinal analysis of previously well patients with initial mild illness carried out by Puntmann et al. showed a somewhat lower, but still significant, incidence of persistent symptoms at 57%9. There is evidence to suggest that residual symptoms in post-COVID-19 syndrome may be related to persistent endothelial dysfunction27.

In terms of the evolution of CMR findings in COVID-19, initial imaging studies on selected patients (those with COVID-19 and elevated troponin levels during hospitalization)28 and unselected patients (those with a range of COVID-19 symptoms)9 demonstrated a high frequency (up to 78%) of cardiac abnormalities. Subsequent CMR studies have identified patients with myocarditis-like imaging patterns at levels higher than in the general population. However, these findings appear less common than originally thought, and in particular, it is important to point out that the incidence of abnormal CMR findings, especially with regard to native and post contrast T1, and T2 values, are dependent on the particular imaging protocols, sequence parameters and postprocessing approaches used by a given centre or by a given study protocol. Joy et al. published results from a nested case–control study that included 74 seropositive participants along with 75 age-, sex-, and ethnicity-matched control subjects selected from volunteering seronegative subjects29. Disease was mild in 99%, with 25% asymptomatic and only 2 hospitalized. Cardiovascular abnormalities on CMR were found to be no more common in seropositive versus seronegative individuals 6 months post mild COVID-19 infection, including 4% with LGE myocardial scarring29. Of note, only 2 patients in this cohort were found to have reduced ejection fraction with a minimum LVEF of 50%. A subsequent study found left ventricular dysfunction present in 11% (17/148) of patients recently recovered from COVID-1930. Furthermore, findings comparing a cohort of patients specifically with the delta variant of COVID-19 (n = 44) and healthy controls revealed no patients with abnormal LVEF and 9% of patients with myocardial late gadolinium enhancement31. Finally, Orbach et al. studied 70 consecutive patients with prior COVID-19 and positive high sensitivity troponin-T requiring hospitalization and found only 9% had late gadolinium enhancement suggestive of myocardial scarring, with LVEF only reduced in 4% of patients32. The findings of our study are in keeping with this latter data, despite the fact that none of our patients had a positive high sensitivity troponin-T value. However, as our serum biomarkers were not taken at the time of the index case, it may simply reflect the fact that troponin levels have normalized by the time our patients had blood samples drawn. Taken together, our data tends to concur with the contemporary literature, in that incidence of myocardial injury in COVID-19 is not as high as originally reported.

There is evidence that infection with COVID-19 leads to changes with regard to protein composition in the serum of infected individuals, which in turn alters the coagulation and inflammation response of that individual33. Fogarty et al. demonstrated that severe COVID-19 infection in hospitalized patients was associated with a significant coagulopathy that correlates with disease severity34. D-Dimer levels may remain elevated in up to 25% of patients up to 4 months post-SARS-CoV-2 infection35,36. Interestingly, the lower levels seen in our study corroborate this, in that we confirm D-dimer levels are elevated in fewer patients in a cohort who did not require hospitalisation. On the other hand, WVF-Ag was, however, found to be elevated in significant proportion of patients, in keeping with data of Philippe et al.25. The relative significance of these contrasting findings merits further study.

Pro-inflammatory markers are frequently significantly raised in patients with severe COVID-1937. Several pro-inflammatory markers were elevated in our study, even in the absence of severe COVID requiring hospitalization. This raises questions with regard to the specificity of these markers for severe infection, which requires further dedicated study.

Implications for research and/or practice

Despite a clear evidence of significant persistent symptom burden, no correlation with objective markers of myocardial injury on CMR was found for most patients in this study. Further investigation is necessary to allow us to glean a better insight as to why symptoms persist.

In contrast, absence of a high prevalence of direct myocardial involvement is reassuring. Future research efforts should therefore be concentrated on a pragmatic approach to dealing with symptoms associated with post-COVID-19 syndrome in general practice. Anti-inflammatory therapies in such patients may prove to be a possible therapeutic option.

Conclusions

In conclusion, this study demonstrates that in patients recovering from COVID-19, cardiac abnormalities on CMR were not infrequent, though generally mild, with late gadolinium enhancement present in 2.2% and abnormal LVEF 17.4% of patients. A prolonged inflammatory state and hypercoagulability was observed in a significant minority of patients and further evaluation of the long-term natural history and clinical importance of these findings in survivors of acute COVID-19 is warranted, especially those with post-acute COVID-19 syndrome.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71535-8.

Author contributions

Author contributions are as following: Conception and design of the work (RC, HR, RJB, MH, JSO’D, RAB); Acquisition, analysis, and interpretation of data for the work (RC, HR, RJB, AM, RL, JB, HW, NB, NB, MF, GS, EH, MH, JSO’D, RAB); Drafting the manuscript or reviewing it critically for important intellectual content (RC, SF, HR, LMcG, RJB, AM, AC, RL, JB, SMcK, GC, DO’C, HW, NB, NB, MF, JMcN, GS, EH, MH, JSO’D, RAB); Final approval of the submitted manuscript (RC, SF, HR, LMcG, RJB, AM, AC, RL, JB, SMcK, GC, DO’C, HW, NB, NB, MF, JMcN, GS, EH, MH, JSO’D, RAB); Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (RC, SF, HR, LMcG, RJB, AM, AC, RL, JB, SMcK, GC, DO’C, HW, NB, NB, MF, JMcN, GS, EH, MH, JSO’D, RAB).

Funding

This work was partly supported by a research grant to RC from Women As One (2021 Escalator award- Research).

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

This study was funded by a Women As One Escalator Research Award 2021, awarded to the lead author, Dr. R. Colleran. R.A. Byrne reports research or educational funding to the institution of current employment from Abbott Vascular, Biosensors, Boston Scientific and Translumina; none of the funding contributes to his personal remuneration. L. McGovern is funded by the European Commission under Horizons 2020 framework (Grant agreement number 965246—CORE-MD). The other authors declare no potential conflicts of interest.

Ethical approval

This study was approved by Mater Misericordiae University Hospital Institutional Review Board (Approval Ref. No. 1/378/2199).

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Akhmerov A Marban E COVID-19 and the heart Circ. Res. 2020 126 10 1443 1455 10.1161/CIRCRESAHA.120.317055 32252591
Akhmerov, A. & Marban, E. COVID-19 and the heart. Circ. Res. 126(10), 1443–1455. 10.1161/CIRCRESAHA.120.317055 (2020).32252591 10.1161/CIRCRESAHA.120.317055
2. Giustino G Croft LB Stefanini GG Bragato R Silbiger JJ Vicenzi M Characterization of myocardial injury in patients with COVID-19 J. Am. Coll. Cardiol. 2020 76 18 2043 2055 10.1016/j.jacc.2020.08.069 33121710
Giustino, G. et al. Characterization of myocardial injury in patients with COVID-19. J. Am. Coll. Cardiol. 76(18), 2043–2055. 10.1016/j.jacc.2020.08.069 (2020).33121710 10.1016/j.jacc.2020.08.069
3. Fried JA Ramasubbu K Bhatt R Topkara VK Clerkin KJ Horn E The variety of cardiovascular presentations of COVID-19 Circulation 2020 141 23 1930 1936 10.1161/CIRCULATIONAHA.120.047164 32243205
Fried, J. A. et al. The variety of cardiovascular presentations of COVID-19. Circulation 141(23), 1930–1936. 10.1161/CIRCULATIONAHA.120.047164 (2020).32243205 10.1161/CIRCULATIONAHA.120.047164
4. Task Force for the management of COVID-19 of the European Society of Cardiology European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1-epidemiology, pathophysiology, and diagnosis Eur. Heart J. 2022 43 11 1033 1058 10.1093/eurheartj/ehab696 34791157
Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1-epidemiology, pathophysiology, and diagnosis. Eur. Heart J. 43(11), 1033–1058. 10.1093/eurheartj/ehab696 (2022).34791157 10.1093/eurheartj/ehab696
5. Ammirati E Lupi L Palazzini M Hendren NS Grodin JL Cannistraci CV Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis Circulation 2022 145 15 1123 1139 10.1161/CIRCULATIONAHA.121.056817 35404682
Ammirati, E. et al. Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis. Circulation 145(15), 1123–1139. 10.1161/CIRCULATIONAHA.121.056817 (2022).35404682 10.1161/CIRCULATIONAHA.121.056817
6. Cenko E Badimon L Bugiardini R Claeys MJ De Luca G de Wit C Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology and Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA) Cardiovasc. Res. 2021 117 14 2705 2729 10.1093/cvr/cvab298 34528075
Cenko, E. et al. Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology and Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc. Res. 117(14), 2705–2729. 10.1093/cvr/cvab298 (2021).34528075 10.1093/cvr/cvab298
7. Xie Y Xu E Bowe B Al-Aly Z Long-term cardiovascular outcomes of COVID-19 Nat. Med. 2022 28 3 583 590 10.1038/s41591-022-01689-3 35132265
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28(3), 583–590. 10.1038/s41591-022-01689-3 (2022).35132265 10.1038/s41591-022-01689-3
8. Raman B Bluemke DA Luscher TF Neubauer S Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus Eur. Heart J. 2022 43 11 1157 1172 10.1093/eurheartj/ehac031 35176758
Raman, B., Bluemke, D. A., Luscher, T. F. & Neubauer, S. Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43(11), 1157–1172. 10.1093/eurheartj/ehac031 (2022).35176758 10.1093/eurheartj/ehac031
9. Puntmann VO Carerj ML Wieters I Fahim M Arendt C Hoffmann J Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 5 11 1265 1273 10.1001/jamacardio.2020.3557 32730619
Puntmann, V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5(11), 1265–1273. 10.1001/jamacardio.2020.3557 (2020).32730619 10.1001/jamacardio.2020.3557
10. Huang L Zhao P Tang D Zhu T Han R Zhan C Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging JACC Cardiovasc. Imaging 2020 13 11 2330 2339 10.1016/j.jcmg.2020.05.004 32763118
Huang, L. et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc. Imaging 13(11), 2330–2339. 10.1016/j.jcmg.2020.05.004 (2020).32763118 10.1016/j.jcmg.2020.05.004
11. Ng MY Ferreira VM Leung ST Yin Lee JC Ho-Tung Fong A To Liu RW Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging JACC Cardiovasc. Imaging 2020 13 11 2476 2478 10.1016/j.jcmg.2020.08.012 33153536
Ng, M. Y. et al. Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging. JACC Cardiovasc. Imaging 13(11), 2476–2478. 10.1016/j.jcmg.2020.08.012 (2020).33153536 10.1016/j.jcmg.2020.08.012
12. Starekova J Bluemke DA Bradham WS Eckhardt LL Grist TM Kusmirek JE Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging JAMA Cardiol. 2021 6 8 945 950 10.1001/jamacardio.2020.7444 33443537
Starekova, J. et al. Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol. 6(8), 945–950. 10.1001/jamacardio.2020.7444 (2021).33443537 10.1001/jamacardio.2020.7444
13. Liu X Wang J Xu X Liao G Chen Y Hu CH Patterns of IgG and IgM antibody response in COVID-19 patients Emerg. Microbes Infect. 2020 9 1 1269 1274 10.1080/22221751.2020.1773324 32515684
Liu, X. et al. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg. Microbes Infect. 9(1), 1269–1274. 10.1080/22221751.2020.1773324 (2020).32515684 10.1080/22221751.2020.1773324
14. Patel MM Thornburg NJ Stubblefield WB Talbot HK Coughlin MM Feldstein LR Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee JAMA 2020 324 17 1781 1782 10.1001/jama.2020.18796 32940635
Patel, M. M. et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 324(17), 1781–1782. 10.1001/jama.2020.18796 (2020).32940635 10.1001/jama.2020.18796
15. Llitjos JF Leclerc M Chochois C Monsallier JM Ramakers M Auvray M High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients J. Thromb. Haemost. 2020 18 7 1743 1746 10.1111/jth.14869 32320517
Llitjos, J. F. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. 18(7), 1743–1746. 10.1111/jth.14869 (2020).32320517 10.1111/jth.14869
16. Goshua G Pine AB Meizlish ML Chang CH Zhang H Bahel P Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study Lancet Haematol. 2020 7 8 e575 e582 10.1016/s2352-3026(20)30216-7 32619411
Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol. 7(8), e575–e582. 10.1016/s2352-3026(20)30216-7 (2020).32619411 10.1016/s2352-3026(20)30216-7
17. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology Heart rate variability Circulation 1996 93 5 1043 1065 10.1161/01.Cir.93.5.1043 8598068
Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Heart rate variability. Circulation 93(5), 1043–1065. 10.1161/01.Cir.93.5.1043 (1996).8598068 10.1161/01.Cir.93.5.1043
18. Rafiee MJ Friedrich MG MRI of cardiac involvement in COVID-19 Br. J. Radiol. 2024 97 1160 1367 1377 10.1093/bjr/tqae086 38656976
Rafiee, M. J. & Friedrich, M. G. MRI of cardiac involvement in COVID-19. Br. J. Radiol. 97(1160), 1367–1377. 10.1093/bjr/tqae086 (2024).38656976 10.1093/bjr/tqae086
19. Bangalore S Sharma A Slotwiner A Yatskar L Harari R Shah B ST-segment elevation in patients with Covid-19—A case series N. Engl. J. Med. 2020 382 25 2478 2480 10.1056/NEJMc2009020 32302081
Bangalore, S. et al. ST-segment elevation in patients with Covid-19—A case series. N. Engl. J. Med. 382(25), 2478–2480. 10.1056/NEJMc2009020 (2020).32302081 10.1056/NEJMc2009020
20. Burkert FR Niederreiter L Dichtl W Mayr A Virgolini I Klauser A Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: The mystery of the phantom embolus or local endothelitis Eur. Heart J. Case Rep. 2021 5 2 ytaa521 10.1093/ehjcr/ytaa521 33598613
Burkert, F. R. et al. Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: The mystery of the phantom embolus or local endothelitis. Eur. Heart J. Case Rep. 5(2), ytaa521. 10.1093/ehjcr/ytaa521 (2021).33598613 10.1093/ehjcr/ytaa521
21. Moady G Atar S Stress-induced cardiomyopathy-considerations for diagnosis and management during the COVID-19 pandemic Medicina (Kaunas) 2022 10.3390/medicina58020192 35208516
Moady, G. & Atar, S. Stress-induced cardiomyopathy-considerations for diagnosis and management during the COVID-19 pandemic. Medicina (Kaunas)10.3390/medicina58020192 (2022).35208516 10.3390/medicina58020192
22. Sardu C Gambardella J Morelli MB Wang X Marfella R Santulli G Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence J. Clin. Med. 2020 10.3390/jcm9051417 32403217
Sardu, C. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med.10.3390/jcm9051417 (2020).32403217 10.3390/jcm9051417
23. Vinciguerra M Romiti S Sangiorgi GM Rose D Miraldi F Greco E SARS-CoV-2 and atherosclerosis: Should COVID-19 be recognized as a new predisposing cardiovascular risk factor? J. Cardiovasc. Dev. Dis. 2021 10.3390/jcdd8100130 34677199
Vinciguerra, M. et al. SARS-CoV-2 and atherosclerosis: Should COVID-19 be recognized as a new predisposing cardiovascular risk factor?. J. Cardiovasc. Dev. Dis.10.3390/jcdd8100130 (2021).34677199 10.3390/jcdd8100130
24. Quinaglia T Shabani M Breder I Silber HA Lima JAC Sposito AC Coronavirus disease-19: The multi-level, multi-faceted vasculopathy Atherosclerosis 2021 322 39 50 10.1016/j.atherosclerosis.2021.02.009 33706082
Quinaglia, T. et al. Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. Atherosclerosis 322, 39–50. 10.1016/j.atherosclerosis.2021.02.009 (2021).33706082 10.1016/j.atherosclerosis.2021.02.009
25. Millard LAC Fernandez-Sanles A Carter AR Hughes RA Tilling K Morris TP Exploring the impact of selection bias in observational studies of COVID-19: A simulation study Int. J. Epidemiol. 2023 52 1 44 57 10.1093/ije/dyac221 36474414
Millard, L. A. C. et al. Exploring the impact of selection bias in observational studies of COVID-19: A simulation study. Int. J. Epidemiol. 52(1), 44–57. 10.1093/ije/dyac221 (2023).36474414 10.1093/ije/dyac221
26. Carfì A Bernabei R Landi F Persistent symptoms in patients after acute COVID-19 JAMA 2020 324 6 603 605 10.1001/jama.2020.12603 32644129
Carfì, A., Bernabei, R. & Landi, F. Persistent symptoms in patients after acute COVID-19. JAMA 324(6), 603–605. 10.1001/jama.2020.12603 (2020).32644129 10.1001/jama.2020.12603
27. Kuchler T Gunthner R Ribeiro A Hausinger R Streese L Wohnl A Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation Angiogenesis 2023 26 4 547 563 10.1007/s10456-023-09885-6 37507580
Kuchler, T. et al. Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation. Angiogenesis 26(4), 547–563. 10.1007/s10456-023-09885-6 (2023).37507580 10.1007/s10456-023-09885-6
28. Knight DS Kotecha T Razvi Y Chacko L Brown JT Jeetley PS COVID-19: Myocardial injury in survivors Circulation 2020 142 11 1120 1122 10.1161/circulationaha.120.049252 32673505
Knight, D. S. et al. COVID-19: Myocardial injury in survivors. Circulation 142(11), 1120–1122. 10.1161/circulationaha.120.049252 (2020).32673505 10.1161/circulationaha.120.049252
29. Joy G Artico J Kurdi H Seraphim A Lau C Thornton GD Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers JACC Cardiovasc. Imaging 2021 14 11 2155 2166 10.1016/j.jcmg.2021.04.011 33975819
Joy, G. et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc. Imaging 14(11), 2155–2166. 10.1016/j.jcmg.2021.04.011 (2021).33975819 10.1016/j.jcmg.2021.04.011
30. Kotecha T Knight DS Razvi Y Kumar K Vimalesvaran K Thornton G Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance Eur. Heart J. 2021 42 19 1866 1878 10.1093/eurheartj/ehab075 33596594
Kotecha, T. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur. Heart J. 42(19), 1866–1878. 10.1093/eurheartj/ehab075 (2021).33596594 10.1093/eurheartj/ehab075
31. Zhang L Wei X Wang H Jiang R Tan Z Ouyang J Cardiac involvement in patients recovering from Delta Variant of COVID-19: A prospective multi-parametric MRI study ESC Heart Fail. 2022 9 4 2576 2584 10.1002/ehf2.13971 35560820
Zhang, L. et al. Cardiac involvement in patients recovering from Delta Variant of COVID-19: A prospective multi-parametric MRI study. ESC Heart Fail. 9(4), 2576–2584. 10.1002/ehf2.13971 (2022).35560820 10.1002/ehf2.13971
32. Orbach A Ghugre NR Biswas L Connelly KA Chan A Strauss BH Low prevalence of late myocardial injury on cardiac MRI following COVID-19 infection J. Magn. Reson. Imaging 2023 58 6 1777 1784 10.1002/jmri.28668 36872614
Orbach, A. et al. Low prevalence of late myocardial injury on cardiac MRI following COVID-19 infection. J. Magn. Reson. Imaging 58(6), 1777–1784. 10.1002/jmri.28668 (2023).36872614 10.1002/jmri.28668
33. Beltran-Camacho L Eslava-Alcon S Rojas-Torres M Sanchez-Morillo D Martinez-Nicolas MP Martin-Bermejo V The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo Mol. Med. 2022 28 1 40 10.1186/s10020-022-00465-w 35397534
Beltran-Camacho, L. et al. The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo. Mol. Med. 28(1), 40. 10.1186/s10020-022-00465-w (2022).35397534 10.1186/s10020-022-00465-w
34. Fogarty H Townsend L Ni Cheallaigh C Bergin C Martin-Loeches I Browne P COVID19 coagulopathy in Caucasian patients Br. J. Haematol. 2020 189 6 1044 1049 10.1111/bjh.16749 32330308
Fogarty, H. et al. COVID19 coagulopathy in Caucasian patients. Br. J. Haematol. 189(6), 1044–1049. 10.1111/bjh.16749 (2020).32330308 10.1111/bjh.16749
35. Townsend L Fogarty H Dyer A Martin-Loeches I Bannan C Nadarajan P Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response J. Thromb. Haemost. 2021 19 4 1064 1070 10.1111/jth.15267 33587810
Townsend, L. et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J. Thromb. Haemost. 19(4), 1064–1070. 10.1111/jth.15267 (2021).33587810 10.1111/jth.15267
36. Lehmann A Prosch H Zehetmayer S Gysan MR Bernitzky D Vonbank K Impact of persistent D-dimer elevation following recovery from COVID-19 PLoS One 2021 16 10 e0258351 10.1371/journal.pone.0258351 34710097
Lehmann, A. et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS One 16(10), e0258351. 10.1371/journal.pone.0258351 (2021).34710097 10.1371/journal.pone.0258351
37. Qin C Zhou L Hu Z Zhang S Yang S Tao Y Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China Clin. Infect. Dis. 2020 71 15 762 768 10.1093/cid/ciaa248 32161940
Qin, C. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71(15), 762–768. 10.1093/cid/ciaa248 (2020).32161940 10.1093/cid/ciaa248
38. Petersen SE Khanji MY Plein S Lancellotti P Bucciarelli-Ducci C European Association of Cardiovascular Imaging expert Consensus Document: A comprehensive review of cardiovascular MR normal values of cardiac chamber size and aortic root in adults and recommendation for grading severity Eur. Heart J. Cardiovasc. Imaging 2019 20 12 1321 1331 10.1093/ehjci/jez232 31544926
Petersen, S. E., Khanji, M. Y., Plein, S., Lancellotti, P. & Bucciarelli-Ducci, C. European Association of Cardiovascular Imaging expert Consensus Document: A comprehensive review of cardiovascular MR normal values of cardiac chamber size and aortic root in adults and recommendation for grading severity. Eur. Heart J. Cardiovasc. Imaging 20(12), 1321–1331 (2019).31544926 10.1093/ehjci/jez232
